Sandu Pharmaceuticals Reports Stable Q1 FY27 Financials

₹16.39 crore revenue, ₹0.23 crore net profit.

Reader Takeaway: Stable financials with consistent profit; shareholders to track dividend record date and AGM.

What just happened

Sandu Pharmaceuticals announced its financial results for the first quarter of FY27 (ending June 30, 2026). The company reported revenue from operations of ₹16.39 crore, a marginal decrease from ₹16.70 crore in the same quarter last year. Net profit remained stable at ₹0.23 crore, slightly up from ₹0.22 crore in the prior year's corresponding quarter. Earnings Per Share (Basic) improved to ₹0.37 from ₹0.23.

Why this matters

The stable financial performance indicates resilience in Sandu Pharmaceuticals' operations. For investors, the key upcoming event is the Annual General Meeting (AGM), for which the Register of Members and Share Transfer Books will be closed from September 4 to September 11, 2026. The dividend record date is set for September 4, 2026, meaning shareholders on this date will be eligible for the proposed dividend for FY26.

The backstory

Sandu Pharmaceuticals has been operating in the pharmaceutical sector, focusing on traditional and herbal medicines. The company's performance typically reflects the broader trends in the Indian pharmaceutical market, particularly the Ayurvedic and herbal segments.

What changes now

Following the results, the focus shifts to corporate actions. Investors are awaiting the AGM where key decisions, including the appointment of statutory auditors, will be finalized. The dividend payout timeline is now clear, providing clarity to shareholders regarding potential returns.

Risks to watch

While the current results are stable, potential risks include increasing competition in the herbal medicine market, regulatory changes, and fluctuations in raw material prices. Any significant deviation from the current revenue and profit trajectory could impact investor sentiment.

Peer comparison

Information on specific peers and their comparative performance for the same quarter is not provided in the filing. However, the pharmaceutical sector, especially the herbal segment, is competitive with several established and emerging players.

Context metrics (time-bound)

Q1 FY27 vs Q1 FY26:

• Revenue: ₹16.39 crore vs ₹16.70 crore (Marginal decline)
• Net Profit: ₹0.23 crore vs ₹0.22 crore (Stable)
• EPS (Basic): ₹0.37 vs ₹0.23 (Improved)

Corporate Actions:

• Register Closure: September 4, 2026 - September 11, 2026
• Dividend Record Date: September 4, 2026
• Auditor Appointment Term: 5 years (subject to shareholder approval)

What to track next

Investors should monitor the outcome of the Annual General Meeting, particularly the shareholder approval for the new statutory auditors. Tracking the company's performance in the upcoming quarters against the backdrop of market conditions will also be crucial.